New cancer pill TQB3217 enters first human tests
NCT ID NCT07291050
First seen Jan 08, 2026 · Last updated Jun 19, 2026 · Updated 20 times
Summary
This early-stage trial tests a new oral drug called TQB3217 in 40 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body processes the drug. Researchers will also look for any early signs that the drug might shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQB3217 tablets (a USP1 inhibitor)
What this could lead to
If it works, this could point toward a new treatment option for advanced cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early, first-in-human trial with only 40 participants. The drug may not be effective or could cause serious side effects. It will take years before any potential treatment is confirmed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.